Back to News
Market Impact: 0.25
Sobi and Innate announce partnership is now effective following completion of closing conditions
Source: PR Newswire
Healthcare & BiotechM&A & Restructuring
Swedish Orphan Biovitrum (Sobi) and Innate Pharma announced that their previously disclosed strategic partnership became effective on Sept. 16, 2026. The notice confirms completion of the partnership’s effectiveness condition but provides no financial terms, program details, or expected revenue impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
IPHA0.65
SOBI0.40
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Jefferies raises West Pharmaceutical stock price target on HVP growth
- People Inc earnings up next after MGM deal collapse
- Mizuho raises Dominion Energy stock price target to $68 on earnings beat
- Wells Fargo raises Abbvie stock price target to $340 on pipeline